Q-omics provides the consensus-scored PODN profile across patient tissues and cancer cell-line models. PODN expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PODN is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, PODN protein abundance shows 31,491 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, THCA, and PDAC as cancer lineages where PODN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PODN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PODN survival associations across molecular data types. PODN RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PODN RNA expression–survival associations across cancer types. High PODN expression shows unfavorable associations in KIRP, OV and ACC, but favorable associations in MESO, LUAD and DLBC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PODN RNA expression.
This table summarizes PODN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PODN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PODN shows lower tumor expression in THCA, KICH, BLCA, UCEC, LIHC and BRCA. The THCA box plot shows higher PODN RNA expression in normal versus tumor tissue (log2 FC = −3.350, t-test p < 0.001).
This table shows molecular features associated with PODN in patient tissues and cancer cell lines. In patient samples, PODN shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PODN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
